IMARC Group, a leading market research company, has recently releases report titled “Antipsychotic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” The study provides a detailed analysis of the industry, including the global antipsychotic drugs market trends, share, size, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the antipsychotic drugs market?
The global antipsychotic drugs market size reached US$ 16.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 28.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.2% during 2024-2032.
Factors Affecting the Growth of the Antipsychotic Drugs Industry:
Rising Prevalence of Psychiatric Disorders:
The escalating incidence of psychiatric disorders like schizophrenia, bipolar disorder, and major depressive disorder globally is a primary driver of the antipsychotic drugs market. Factors such as urbanization, lifestyle changes, and genetic predispositions contribute to this rise. As these disorders often require long-term treatment, there is a sustained demand for antipsychotic medications. Additionally, increased awareness and reduced stigma surrounding mental health have encouraged more individuals to seek diagnosis and treatment, further boosting the demand for these drugs.
Increasing Awareness about Mental Health:
A growing recognition of the significance of mental health and the need for timely intervention has led to heightened awareness globally. Efforts from healthcare organizations, advocacy groups, and media campaigns have played a crucial role in educating the public about psychiatric disorders and the available treatment options, including antipsychotic drugs. This increased awareness has resulted in early detection and treatment of mental health conditions, driving up the demand for antipsychotic medications.
Advancements in Medical Technology and Drug Delivery Systems:
Technological advancements in the field of medicine and pharmaceuticals have revolutionized drug delivery systems, making antipsychotic medications more effective and tolerable for patients. Innovations such as extended-release formulations, transdermal patches, and intramuscular injections have improved patient compliance and therapeutic outcomes. Additionally, advancements in neuroscience and pharmacology have facilitated the development of newer, more targeted antipsychotic drugs with enhanced efficacy and fewer side effects, further propelling market growth.
Request for a sample copy of this report: https://www.imarcgroup.com/antipsychotic-drugs-market/requestsample
Antipsychotic Drugs Market Report Segmentation:
Breakup By Therapeutic Class:
- First Generation
- Haldol
- Navane
- Others
- Second Generation
- Invega
- Latuda
- Seroquel
- Risperdal
- Zyprexa
- Geodon
- Others
- Third Generation
- Abilify
Second-generation drugs represented the largest segment by therapeutic class due to their improved efficacy and reduced risk of side effects compared to first-generation antipsychotics.
Breakup By Application:
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
Schizophrenia accounted for the largest segment by application because it is one of the most prevalent psychiatric disorders globally, necessitating long-term treatment with antipsychotic medications.
Breakup By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Retail pharmacies emerged as the largest distribution channel due to their widespread accessibility and convenience for patients seeking regular prescriptions for psychiatric medications.
Breakup By Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America became the largest market due to factors such as high prevalence rates of psychiatric disorders, advanced healthcare infrastructure, and greater affordability and accessibility of antipsychotic medications in the region.
Global Antipsychotic Drugs Market Trends:
The global antipsychotic drugs market is driven by several factors shaping its trajectory, such as the rising prevalence of psychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder across the globe is a significant driver, propelling the demand for antipsychotic medications. In line with this, increasing awareness about mental health disorders and the importance of early diagnosis and treatment has led to a higher rate of prescription and consumption of antipsychotic drugs. Additionally, advancements in medical technology and drug delivery systems have facilitated the development of more effective and targeted therapies, expanding the market size. Moreover, the growing geriatric population worldwide, who are more prone to mental health issues, contributes to the expansion of the antipsychotic drugs market.
Who are the key players operating in the industry?
The report covers the major market players including:
- AbbVie Inc.
- Alkermes plc
- Dr. Reddy’s Laboratories Ltd.
- Johnson & Johnson
- Otsuka Pharmaceutical Co. Ltd.
- Viatris Inc.
Browse the full report with TOC and list of Figures: https://www.imarcgroup.com/antipsychotic-drugs-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
